Currently Available Assays

 

 

Syncitium International is strongly committed to fully investigate and understand the potential value of genotyping in improving the safety and efficacy of cancer therapy

 

 
Syncitium International Central Lab Provides pharmacogenetic Testing for Cancer Therapy

 

For

 

§          Pharmacogenomic Screening of patients enrolled in clinical trials

 

§          Genetic polymorphism involved in safety and/or efficacy of drugs

 

§          SNP determination

 

§          Pharmacogenomic profiling

 

7 Sep 2004    MDR1 P-glycoprotein
(ABCB1)
 
7 Sep 2004    DNA-repair enzyme
(XRCC1)
 
7 Sep 2004    carboxylesterases
(CES1, CES2)
 
7 Sep 2004    cytochrome P450 isozymes
(CYP3A4, CYP3A5)
 
7 Sep 2004    Multidrug resistance-associated proteins
MRP-1 (ABCC1) and MRP-2 (ABCC2)
 
7 Sep 2004    UDP glucuronosyltransferases

UGT1A1 (UGT1A1*28) and UGT1A9

 

 

 
                       Quality Service

 

 

§          Adherence to study plan

 

§          Sample handling/storage compliant with Good Laboratory Practices

 

§          Complete transparency in experimental execution MIAME / MGED guidelines

 

§          Full traceability from simple receipt to final report

 

§          Data archiving